GM splits GE Healthcare; Coronary stent national procurement "second season" bidding; "Brain-computer interface" will be filed for clinical use in the United States

According to the Wall Street Journal on December 1, GE finalized the terms of spinning off its healthcare unit, GE Healthcare, and the soon-to-be public company has an initial value of about $31 billion
.

GE said existing shareholders will receive 1 share
of new company GE HealthCare Technologies for every 3 GE shares they hold.
The spin-off is scheduled to take place after the close of business on January 3 next year, and the new shares will be traded on the NASDAQ under the ticker symbol "GEHC"
.

GE Healthcare, the healthcare business unit of the GE Group, is committed to becoming an innovator leading the way in precision medicine
.
It mainly provides intelligent equipment, data analysis, software applications and services to realize a comprehensive precision medicine ecosystem from disease diagnosis, treatment to monitoring
.

GE plans to spin off into three separate publicly traded
companies in early 2024.
Following the spin-off of its healthcare business, GE plans to split
its aerospace business from its power and renewable energy divisions.

After the spin-off, GE Healthcare will consist of four business units – Medical Imaging, Ultrasound, Life Care and Diagnostic Medicine
.
The main business of the four departments are: medical imaging, ultrasound, life care, and diagnostic drugs
.

It is reported that GE Healthcare mainly produces medical imaging equipment and other medical devices, with annual revenue of about $18 billion, and GE's revenue in 2021 was $74.
2 billion.

According to GE's financial report in 2021, GE Healthcare accounted for about
a quarter of GE's total revenue.

On October 25, 2022, GE Group announced its third-quarter results, of which GE Healthcare's sales in the third quarter of 2022 were US$4.
613 billion (approximately RMB33.
882 billion), a year-on-year increase of 6.
3%.

Net income was $712 million, up 1.
1%
year-over-year.
Increased orders for medical imaging and ultrasound equipment drove GE Healthcare's revenue growth
in the third quarter.
For the same period, equipment sales rose 8 percent to $2.
35 billion and services revenue rose 5 percent to $2.
26 billion
.

In recent years, not only GE, but also giants such as Johnson & Johnson, GSK, Medtronic, and 3M have been spinning off their businesses, and the trend of business models from scale to refinement has been set
.
On the one hand, in order to focus more on high-profit and high-growth medical products, on the other hand, the global pharmaceutical and health consumer market is undergoing drastic changes, and at the same time, the policy environment in some key country markets is also changing
.
In order to adapt to the new development environment, multinational pharmaceutical companies are accelerating change
.

What other "equipment" news is worth paying attention to in the medical equipment circle this week? Industry new policy insights, enterprise new trend observation, market investment and financing review, "Medical Economic News" new media center tracking report!

1.
The third batch of medical device unique identification work will be started

On November 30, the General Department of the State Food and Drug Administration issued the "Announcement on the Third Batch of Implementation of Unique Identification of Medical Devices (Draft for Comments)" (hereinafter referred to as the "Draft for Comments"
).

The Draft points out that, according to the degree of risk and regulatory needs, some Class II medical devices such as disposable products with large clinical demand, varieties included in the scope of medical insurance centralized procurement, and medical cosmetology-related products will be identified as the unique identification implementation varieties
of the third batch of medical devices.

The "Third Batch of Product Catalogue for the Implementation of Unique Identification of Medical Devices" includes 141 kinds of medical devices, such as ultrasonic surgery equipment accessories, medical laser optical fibers, high-frequency surgical equipment, electric staplers, vascular suture devices, optical endoscopes, electronic endoscopes, peritoneal dialysis equipment, pacing system analysis equipment, biopsy needles, protective clothing, hearing aids, blood cell analysis instruments, etc
.

2.
The average winning price is about 770 yuan, and the "second quarter" of coronary stents is opened

On November 29, the National Joint Procurement Office for High-value Medical Consumables carried out the continuation of the next cycle of centralized procurement of coronary stents in Changzhou
, Jiangsu Province.
This is a big test
for coronary intervention consumables companies to accept again after the first centralized procurement of coronary stents organized by the state on November 5, 2020.

For the first time, the continuation procurement explored the unified continuation work nationwide, with a total of 3,696 medical institutions participating and purchasing about 1.
78 million.

A total of 14 products from 10 enterprises were qualified to be selected, and a total of 14 products were selected to belong to 10 domestic and foreign enterprises such as Medtronic, Boston Scientific, MicroPort, Lepu, Bluesail, Sino, etc.
, with a selection rate of 91%.

The average price of the selected bracket is about 770 yuan, plus the accompanying service fee, the terminal price range is 730 yuan to 848 yuan
.
It is expected that patients will use the selected products
purchased in January 2023.

3.
Tens of billions of financial funds are issued, which is beneficial to the equipment industry

On November 29, the Department of Social Security of the Ministry of Finance issued the Notice of the Ministry of Finance, the National Health Commission, and the State Administration of Traditional Chinese Medicine on Issuing the 2023 Subsidy Fund Budget for Medical Services and Security Capacity Improvement (Comprehensive Reform of Public Hospitals) in Advance.

According to the subsidy fund allocation table, the 2023 comprehensive reform subsidy fund issued by the state in advance will exceed 10 billion yuan
.

According to the "Guiding Opinions on the Pilot Comprehensive Reform of Urban Public Hospitals" issued by the General Office of the State Council, the comprehensive reform of public hospitals also includes the implementation of capital construction and equipment purchase of public hospitals, equipped with corresponding large-scale medical equipment
.
At the same time, the document emphasizes that public hospitals should give priority to the allocation of domestic medical equipment
.

There is no doubt that the tens of billions of financial funds issued in advance, while improving the medical services of public hospitals across the country, will inevitably drive the upgrading and updating of relevant medical equipment, which is beneficial to the medical equipment industry
.

4.
The online reporting function of serious adverse events and project progress of medical device clinical trials was launched on December 1

In order to implement the requirements of the newly revised "Good Clinical Practice for Medical Devices" and facilitate Guangdong Province sponsors to report serious adverse events and project progress in a timely manner, the Guangdong Medical Products Administration has adjusted some business functions of the "Smart Drug Administration" licensing information system, which has been put into use
since December 1.
Notice of relevant matters is as follows:

1.
When sponsors in the province report serious adverse events in medical device clinical trials, they can log in to the Guangdong Provincial Government Service Network, select the corresponding "Report" option in the completed medical device clinical trial projects, fill in the formatted form content online, and upload the scanned copy of the stamped version of the "Medical Device / In Vitro Diagnostic Reagent Clinical Trial Serious Adverse Event Report Form", confirm that it is correct and submit it after checking the legal statement, that is, the report
is completed.

2.
When the sponsor in the province reports the progress of the termination/completion of the clinical trial of the medical device, he can log in to the Guangdong Provincial Government Service Network, select the corresponding "Report" option in the medical device clinical trial project that has been recorded, upload the scanned copy of the sealed version of the situation description, confirm that it is correct and submit it after checking the legal statement, that is, the report
is completed.

3.
If a sponsor outside the province reports serious adverse events in a medical device clinical trial, it will still send a paper report form
with an official seal through offline channels.

1.
The richest man Musk's "brain-computer interface" company applied for a human test

On December 1, Elon Musk, the world's richest man, said that his brain-computer interface company, Neuralink, would conduct human trials within six months to implant a wireless device into
the brains of subjects.
At present, most of the materials required for this experiment have been submitted to the US FDA
.

Neuralink was founded in
2016.
In Musk's original vision, Neuralink would develop a chip that would connect the human brain to electronic devices, eventually cure brain diseases such as Parkinson's and Alzheimer's, and even integrate the brain with artificial intelligence
.

At the end of December 2021, Musk publicly stated that he hoped to complete the first brain-computer interface human trial
in 2022.
Neuralink's biggest achievement so far, though, has been training a monkey to play video games
telepathically.

2.
Becton Medical and NanoString joined hands to open strategic cooperation in the field of single-cell spatial multiomics

On December 1, 2022, BIDI Medical and NanoString, a global pioneer in space biology, jointly announced that they will start a strategic cooperation in the field of single-cell spatial multiomics, combining the advantages of both parties to provide one-stop technical tools and services
for domestic basic scientific research, clinical research and biomedical research and development.

It is understood that this cooperation will combine the world's leading single-cell multi-omics and spatial omics technologies, focus on future-oriented scientific research and clinical application scenarios, and create an end-to-end full-link solution
.

3.
4.
6 billion, Boston Scientific reached an acquisition

On November 29, it is reported that Boston Scientific announced on the same day that it had reached a definitive agreement to acquire Apollo Endosurgery
.

It is reported that the transaction is Boston Scientific's acquisition of the other party at a cash price of
nearly US$650 million (about 4.
6 billion yuan) per share of US$10.
Boston Scientific said it expects to close the deal
in the first half of 2023.

Apollo Endosurgery is a medical technology company focused on developing next-generation less invasive devices to advance therapeutic endoscopy aimed at treating a variety of gastrointestinal disorders, including closure of gastrointestinal defects, management of gastrointestinal complications, and treatment
of obesity.
One of
the market share leaders for less invasive devices to deal with obesity.

1.
Shengxiang Biotechnology: The upper limit of the repurchased share price is adjusted to not exceed 34.
15 yuan per share

Recently, Shengxiang Biotech announced that after the implementation of the 2022 quarterly equity distribution, the upper limit of the company's repurchase price in centralized bidding transactions was adjusted from no more than 35.
00 yuan / share (inclusive) to no more than 34.
15 yuan / share (inclusive).

On August 28, 2020, Shengxiang Biotech was listed
on the Science and Technology Innovation Board of the Shanghai Stock Exchange.
As of November 30, 2022, the Company has not repurchased shares
through the Shanghai Stock Exchange trading system through centralized auction trading.

2.
Wantai Biotech: As of November 30, a total of 200 million yuan has been repurchased 1.
5832 million shares of the company

Recently, Wantai Biotech announced that the company has repurchased a total of 1,583,200 shares through centralized bidding transactions, the proportion of repurchased shares to the company's total share capital is 0.
17%, the highest price of the repurchase transaction is 133 yuan / share, the lowest price is 112.
74 yuan / share, and the total amount of funds paid is 200 million yuan (excluding transaction fees such as transaction commissions).

Wantai Biotech has repurchased a total of 1,583,200 shares through centralized bidding transactions, the proportion of repurchased shares to the company's total share capital is 0.
17%, the highest price of the repurchase transaction is 133 yuan / share, the lowest price is 112.
74 yuan / share, and the total amount of funds paid is 200 million yuan (excluding transaction fees such as transaction commissions).